The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

Cancer incidence continues to rise for many common cancers—especially for women. The incidence rate for women younger than 50 ...

GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...

More testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...